Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster ...

It's also a great place to start if you're looking for dividend stocks, as nearly every stock on the Dow Jones Industrial ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

Merck (NYSE:MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Exciting developments in cancer treatment were unveiled at the AACR meeting. Boehringer Ingelheim's zongertinib shows a 71% ...

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...